Elevated serum levels of S100 and survival in metastatic malignant melanoma

Buer, Jan; Probst, M.; Franzke, Anke; Duensing, Stefan; Haindl, Johann; Volkenandt, Matthias; Wittke, Frederick; Hoffmann, Reinhard; Ganser, Arnold; Atzpodien, Jens

doi:10.1038/bjc.1997.232

Cited by 70 publications

(53 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38]48 In 2 cases, 26,29 the Authors reported survival analysis separately for 2 subpopulations that differed by TNM stage: since these subpopulations were completely independent, we considered them separately (Table I).…”

Section: Characteristics Of Identified Studiesmentioning

confidence: 99%

“…[13][14][15] The prognostic potential of S100B serum levels is supported by many reports in the literature. [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37] Nevertheless, some investigators found no association between S100B detection and patients' survival 26,29 ; moreover, others reported that S100B has a prognostic value at univariate but not multivariate survival analysis, 38 which would rule out the value of this biomarker as a prognostic factor independent of the already established prognostic power of the TNM staging system.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The prognostic value of serum S100B in patients with cutaneous melanoma: A meta‐analysis

Mocellin

Zavagno

Nitti

2008

Intl Journal of Cancer

View full text Add to dashboard Cite

S100B protein detected in the serum of patients with cutaneous melanoma has been long reported as a prognostic biomarker. However, no consensus exists on its implementation in the routine clinical setting. This study aimed to comprehensively and quantitatively summarize the evidence on the suitability of serum S100B to predict patients' survival. Twenty-two series enrolling 3393 patients with TNM stage I to IV cutaneous melanoma were reviewed. Standard meta-analysis methods were applied to evaluate the overall relationship between S100B serum levels and patients' survival (meta-risk). Serum S100B positivity was associated with significantly poorer survival (hazard ratio [HR] 5 2.23, 95% CI: 1.92-2.58, p < 0.0001). Between-study heterogeneity was significant, which appeared to be related mainly to dissemination bias and the inclusion of patients with stage IV disease. Considering stage I to III melanoma (n 5 1594), the meta-risk remained highly significant (HR 5 2.28, 95% CI: 1.8-2.89; p < 0.0001) and studies' estimates were homogeneous. Subgroup analysis of series reporting multivariate survival analysis supported S100B as a prognostic factor independent of the TNM staging system. Our findings suggest that serum S100B detection has a clinically valuable independent prognostic value in patients with melanoma, with particular regard to stage I-III disease. Further investigation focusing on this subset of patients is justified and warranted before S100B can be implemented in the routine clinical management of melanoma.

show abstract

Section: Characteristics Of Identified Studiesmentioning

confidence: 99%

mentioning

confidence: 99%

The prognostic value of serum S100B in patients with cutaneous melanoma: A meta‐analysis

Mocellin

Zavagno

Nitti

2008

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…So far, only one report has been published which concluded that S100B is unlikely to provide any additional information in a multivariate analysis of stage IV melanoma patients [19]. However, in this study, the chosen cut-off value was 3.0 µg/l [19], which is about 15 times higher than in all other published reports on S100B-IRMA in serum [15, 16, 17, 18].…”

Section: Discussionmentioning

confidence: 75%

“…In recently published studies [15, 16, 17, 18, 19], serum S100B levels were determined in melanoma patients with the aim of using S100B as a clinically relevant marker for metastatic disease. In a report by von Schoultz et al [16], statistically significant associations between the length of survival and serum levels of S100B were presented [16].…”

Section: Introductionmentioning

confidence: 99%

S100B Protein Detection in Serum Is a Significant Prognostic Factor in Metastatic Melanoma

et al. 1999

View full text Add to dashboard Cite

The serum detection of S100B, a new melanoma marker, has shown clinical significance in early studies. The aim of our study of 1,339 serum samples from 412 different melanoma patients and 107 control patients was to prove the prognostic value of serum S100B levels in melanoma patients at different stages of disease and at follow-up (median: 30 months). Using a cutoff level of 0.2 μg/l S100B, 5 of 286 patients (1.7%) with primary tumors (stage I/II), 14/73 (19.2%) patients with locoregional metastasis (stage III) and 57/84 (67.9%) patients with advanced disease (stage IV) were S100B positive (statistically significant differences for stage I/II vs. III, I/II vs. IV, and III vs. IV, p < 0.001). The estimated overall survival time was significantly longer (p < 0.001) for patients with S100B values below 0.2 μg/l compared to patients with elevated S100B levels (≥0.2 μg/l), which was independent of the stage of disease (I–IV). Regarding prognosis, we were furthermore able to distinguish different subgroups among stage III and IV patients using S100B serum levels (p < 0.01). Patients with different cutaneous non-melanoma diseases served as S100B-negative controls. S100B serum evaluations using the Sangtec^®100 IRMA are highly specific and sensitive for the detection of metastatic melanoma. S100B has been shown to be a relevant prognostic factor for survival in a study with a large sample size of melanoma patients including close follow-up evaluations.

show abstract

“…24 However, other studies have not found that S100B adds any information to known clinical prognostic parameters on multivariate analysis. 29,30 S100B also has value in monitoring patients during therapy, with increasing levels being correlated with progressive disease and decreasing levels with disease regres-…”

Section: Lactate Dehydrogenasementioning

confidence: 99%